Midstream Urine: Klebsiella pneumoniae (KPC producer) – Shipped May 2014
The challenge was a simulated midstream urine obtained from a 56 year old male patient from Montreal with flank pain and was sent to cate-gory A laboratories.
Laboratories were expected to isolate, identify, and report Klebsiella pneumoniae. Participants were asked to report susceptibility results to the following antimicrobial agents: 3rd generation cephalosporins, carbapenems, aminoglycosides, trimethoprim-sulfamethoxazole (SXT), piperacillin-tazobactam, and ciprofloxacin. Laboratories were also expected to report the isolate to Infection Control because it is a carbapenem-resistant Enterobacteriaceae (CRE).
MAIN EDUCATIONAL POINTS from M141-4
- Carbapenemase-producing Enterobacteriaceae (CPE) are frequently multi-drug resistant and require expanded antimicrobial susceptibility testing.
- Clinical laboratories need to be able to identify carbapenem-resistant Enterobacteriaceae (CRE) and have an established pro-cedure to determine if these isolates are CPE. Potential isolates of CPE (i.e., CRE) should be reported to Infection Control.